What Ergofein Treats: Main Uses and Benefits

Ergofein is commonly used in clinical settings that involve acute or unstable symptom patterns, a category of conditions characterized by periods of heightened symptoms. This is commonly used in situations involving recurrent or episodic manifestations, such as migraine. It is applied in contexts where short-term symptom management is appropriate. It is relevant across therapeutic domains where additional symptomatic support is needed.

The main therapeutic purpose is to contribute to easing the intense pain of the episode, which may assist with maintaining a sense of stability when symptoms are more noticeable. It is also relevant for easing the overall symptom burden by addressing symptom clusters that may become disruptive, such as nausea and vomiting. By easing these symptoms, the medication supports patients during episodes of heightened discomfort.

“It provides supportive relief when symptoms interfere with routine activities.”

---

Quick Look: Supportive Management for Physical Discomfort and Systemic Imbalance

Regulatory References

1. DailyMed entry on Ergotamine and Caffeine

Eligibility Scope for Ergofein

Ergofein (Ergotamine) is an acute medication with strict population-based eligibility rules defined by regulatory authorities.

Category	Regulatory Status/Wording
Populations for whom use is allowed	Adults (generally 18–65 years) without a pre-existing contraindication.
Populations for whom use is contraindicated	Patients with Ischemic Heart Disease (including history of heart attack or angina), Uncontrolled Hypertension, or Peripheral Arterial Disease.
Condition-specific eligibility rules	Contraindicated in patients with Impaired Hepatic or Renal Function and those with Sepsis.
Concomitant Use Restriction	Contraindicated with the use of potent CYP3A4 Inhibitors (e.g., certain antibiotics or HIV medications).
Pregnancy and lactation eligibility	Contraindicated in Pregnancy (official Category X); Not Recommended during Lactation due to potential infant risk.
Age-related eligibility rules	Safety and efficacy not established in the pediatric population (under 18 years). Use is generally not recommended in patients over 65 years.

These official statements establish multiple absolute prohibitions for use, primarily due to the risk of severe vasoconstriction (ischemia) and systemic toxicity. The medicine is restricted solely to the acute treatment setting and is not for chronic daily administration.

Interactions with other medicines and products

The interaction profile for Ergofein is governed by its metabolic clearance and its primary pharmacologic effect, resulting in several mandatory regulatory restrictions.

Contraindicated Combinations

Co-administration of Ergofein with several classes of medicinal products is contraindicated due to the risk of severe toxicity, including peripheral ischemia. This highest-severity classification applies to potent CYP3A4 inhibitors, such as specific macrolide antibiotics (e.g., Clarithromycin) and protease inhibitors (e.g., Ritonavir). These combinations are prohibited because they block the primary metabolic pathway for Ergofein, officially leading to a significant increase in serum levels and exposure.

---

Pharmacodynamic and Timing Restrictions

Other vasoconstrictive agents and 5-HT₁ agonists (Triptans) are also contraindicated. This restriction stems from a pharmacodynamic synergism where the combined action on blood vessels results in an additive risk of vasospasm. A strict, mandatory separation of 24 hours is required between the administration of Ergofein and any Triptan or other ergot-type medication.

---

Non-Medicinal and Population Interactions

Interactions are also documented with Grapefruit Juice, which inhibits the CYP3A4 enzyme and can increase exposure, and with Nicotine, which may potentiate the vasoconstrictive effect. Use is contraindicated in patients with severe hepatic or renal impairment due to the official finding of reduced drug clearance and potential for accumulation.

How Ergofein Works

The action of Ergofein (Ergotamine) is defined by a dual-pronged pharmacological mechanism within the trigeminovascular system, simultaneously influencing both the vascular and neural components of the underlying process.

Molecular Mechanism: Dual Receptor Agonism

Ergofein functions as a non-selective agonist, principally engaging the mathbf5- HT1 B and mathbf5- HT1 D serotonin receptors, alongside significant interaction with alpha-adrenergic receptors. This interaction pattern targets signaling patterns characteristic of acute vascular and neurogenic processes, initiating molecular steps that shape systemic physiological outcomes. This non-selective binding modulates activity across multiple relevant pathways.

Physiological Cascade: Vasoconstriction and Signal Suppression

Activation of the mathbf5- HT1 B receptors causes the smooth muscle in the extracranial blood vessels to contract, leading to vasoconstriction. This physiological adjustment results in an altered vascular state by reducing the distension and pulsation of the cranial arteries. Simultaneously, activation of mathbf5- HT1 D receptors on peripheral nerve terminals halts the exocytosis of vasoactive neuropeptides (such as CGRP), thereby suppressing the neurogenic inflammation cascade. This leads to the modulation of local physiological responses and reduces the influence of excessive mediator activity on the surrounding tissues.

How to Use Ergofein

The application of Ergofein (Ergotamine Tartrate) emphasizes its role in the acute management of severe headache episodes, and it is prohibited for chronic daily administration. Standard protocols define specific routes, timing, and dose limits that must be observed.

---

Administration Routes and Dosing Patterns

The medication is administered via two primary routes, each with distinct dosing and usage protocols:

Property	Sublingual Tablet (2 mg)	Rectal Suppository (2 mg Ergotamine Content)
Initial Dose	2 mg (one tablet)	One suppository
Repeat Schedule	May be repeated after 30 minutes	May be repeated after 1 hour
Maximum per Attack	Not to exceed 6 mg (3 tablets)	Not to exceed 2 suppositories
Maximum per Week	Not to exceed 10 mg (5 tablets)	Not to exceed 5 suppositories

---

Procedural and Time-Based Instructions

Administration must commence at the first sign of an attack for maximum effect. For the sublingual form, the tablet must be placed under the tongue and allowed to dissolve fully; it must not be chewed or swallowed. The rectal route is typically utilized when the oral route is compromised, such as by severe nausea. If a dose is missed, it should be taken as soon as possible, but if it is almost time for the next scheduled dose, the missed dose must be skipped, and doses should not be doubled. The safety and efficacy of this medication have not been established in pediatric patients.

Research Evidence / Overview of Studies for Ergofein

Evidence from Studies on Acute Migraine

This section summarizes the structure of the clinical research focused on evaluating interventions for a single, acute episode of severe headache. It describes the type of randomized controlled trials (RCTs) and other short-term studies that have measured outcomes like pain relief, pain freedom, and symptom recurrence.

Research exploring short-term symptom study scenarios associated with Ergofein primarily involves older placebo-controlled Randomized Controlled Trials (RCTs), where a comparison was made against an inactive substance. In these trials, researchers examined outcomes related to physical discomfort. They monitored whether patients achieved pain freedom or a significant reduction in headache severity within short observation periods, such as 2 or 4 hours post-dose. Studies also explored changes in associated symptoms like nausea and vomiting, and the frequency of headache recurrence.

Findings describe patterns observed in studies where differences in measured pain relief outcomes were reported compared to placebo in some historical settings. However, the evidence base includes results that were mixed, with some older trials reporting varied measured observations. Data also show patterns related to low or variable absorption (bioavailability), particularly when administered as an oral tablet, and these varying absorption characteristics were a focus of studies comparing different forms.

---

Research Context for Chronic or Recurrent Headaches

This part details the types of non-randomized and observational studies that have examined patterns of use over extended periods. Research examined long-term outcomes related to systemic or functional imbalance over time. Patterns of association were described in the research between long-term, high-frequency use and the development of additional headache patterns, which clinicians sometimes refer to as medication-overuse headache.

However, data are still emerging, and there is limited information for long-term outcomes for sustained treatment effect. Follow-up durations were limited in terms of prospective, controlled studies. The research provides context but not individual predictions, as studies of this nature are observational.

Key Studies & References

1. Ergotamine and Caffeine: MedlinePlus Drug Information (Authoritative Patient Resource)

Common questions about Ergofein (FAQ)

---

Q: What is Ergofein used for?

Regulatory documents state that Ergofein is approved for use in the short-term treatment of moderate to severe acute pain. It is classified as an opioid analgesic, which works to change how the brain and nervous system respond to pain signals. The official product information specifies its use only when non-opioid treatments are considered insufficient.

---

Q: How quickly does Ergofein start working?

According to the official product information, Ergofein typically begins to produce an effect within 30 to 60 minutes after taking the prescribed oral dose. Regulatory data suggests the full pain-relieving effect may typically be reached about one to two hours after administration. This characteristic contributes to its regulatory approval for managing sudden, acute pain.

---

Q: How should Ergofein be stored?

Official information indicates that Ergofein should be stored at room temperature, which is typically between 68 F and 77 F (20 C and 25 C). The official guidance states the medication should be kept away from light and moisture to help maintain its stability and effectiveness. Like all medicines, it must be stored safely out of the sight and reach of children and pets.

---

Q: What happens if I forget to take a dose of Ergofein?

Official product information provides specific instructions on managing missed doses, which usually depend on the timing of the next scheduled dose. The regulatory caution emphasizes that patients should never take more than the prescribed amount or take two doses close together, due to the risk of serious adverse effects. Detailed advice is contained within the dedicated 'How to use Ergofein' section of the product information.

---

Q: Is Ergofein safe to use during pregnancy?

Official product labeling states that Ergofein should be used during pregnancy only if the potential benefit is judged to justify the potential risk to the fetus. Regulatory information suggests potential risks, especially if used near the time of delivery, including withdrawal symptoms in the newborn. The official prescribing information indicates that a prescriber must carefully assess the balance of risk and benefit before deciding on use during pregnancy.

---

Q: Can I take Ergofein if I am breastfeeding?

According to the official product information, the active ingredient in Ergofein is known to pass into breast milk. Regulatory sources recommend caution when administering Ergofein to a nursing mother, as potential effects like sedation or breathing problems in the infant have been observed. The decision to continue nursing or to discontinue the medication is based on a professional risk assessment by a healthcare provider.

---

Q: What is the risk of addiction or dependence with Ergofein?

Official information notes that Ergofein, as an opioid, carries a risk of physical dependence and addiction, even when used as prescribed. Regulatory documents observe that this risk may be greater with long-term use, though it remains a consideration even during short-term treatment. The official prescribing principle is to use the lowest effective dose for the shortest possible duration to help mitigate the risk of developing dependence.

---

Q: What should I do if I take too much Ergofein (overdose)?

Regulatory documents state that an overdose of Ergofein is a life-threatening medical emergency. The official product labeling states that symptoms of overdose may include shallow breathing, extreme drowsiness, slowed heart rate, and loss of consciousness. If an overdose is suspected, regulatory guidance strongly advises seeking immediate emergency medical assistance.

How to Store and Dispose of Ergofein

The official labeling for Ergofein mandates specific storage and disposal requirements to maintain its stability and ensure safety.

Storage Requirements

Condition	Regulatory Requirement
Temperature	Store at Controlled Room Temperature, 20 C to 25 C ( 68 F to 77 F).
Protection	Keep in the original container, tightly closed, and protect from light and moisture.
Safety	Keep the medicine out of the sight and reach of children.

---

Disposal Instructions

Unused or expired Ergofein must be disposed of according to local regulations or by using an official drug take-back program. The product should not be thrown into household waste or flushed down the toilet to prevent environmental contamination.